Can RA-223 improve Enzalutamide efficacy for early castration resistant prostate cancer?

December 09, 2015

Globally, prostate cancer is the second most common type of cancer and the fifth leading cause of cancer-related death in men.

Prof. Bertrand Tombal of the Cliniques Universitaires Saint-Luc in Brussels, Belgium, and Coordinator of this study says, "For men with advanced disease, the objective is to control the disease while maintaining quality of life. Here, androgen deprivation therapy is generally administered initially, but often patients become resistant to this treatment."

The new standards of care for these so called "castration resistant" patients are the new androgen receptor pathways inhibitors enzalutamide (Xtandi™) and abiraterone. Administrated in asymptomatic or moderately symptomatic patients, they delay treatment with chemotherapy, onset of significant pain, and deterioration of quality of life while improving overall survival.

RA-223 (Xofigo®) is a drug that specifically targets bone metastases, the predominant metastatic site in early castration resistant prostate cancer patients. RA-223 has been used at a later stage of the disease when patients were symptomatic.

EORTC trial 1333 has now opened to investigate whether an upfront combination of enzalutamide and RA-223 would improve radiological progression-free survival compared to enzalutamide alone in patients with castration resistant prostate cancer metastatic to bone.

Prof. Silke Gillessen (photo) of the Kantonsspital St Gallen in Switzerland and Co-Coordinator of this study says, "The combination of enzalutamide and RA-223 could attack two important features of metastatic castration resistant prostate cancer. One of these is an adaptation by cancer cells so that they continue to stimulate the androgen receptor pathway, thus simulating cancer (re)growth. The other is their ability to grow in places where bone remodeling has been disrupted."

"Enzalutamide prevents androgens from binding to their receptor, and RA-223, by mimicking calcium, targets areas of bone metastases," adds Prof. Gillessen. "The fact that the safety profiles of both drugs for the most part do not overlap and both treatments are generally well tolerated makes them interesting combination partners. Furthermore RA-223 offers an additional mechanism of action when combined with enzalutamide that is approved for this indication, which makes them a potentially effective combination, too."

The men in the experimental arm will receive the combination of enzalutamide and RA-223 treatment, and the men in the standard arm will receive enzalutamide alone.

The intergroup EORTC trial 1333 is coordinated by the EORTC Genito-Urinary Cancers Group in collaboration with the Academic and Community Cancer Research United and the Ireland Cooperative Oncology Research Group. It plans to accrue 560 patients at 59 institutions located in ten countries: Belgium, Denmark, France, Germany, Republic of Ireland, Italy, Poland, Spain, Switzerland, the United Kingdom, and the United States of America.
-end-
This randomized phase 3 trial is supported by an educational grant provided by Bayer HealthCare Pharmaceuticals Inc. that also provides RA-223 (Xofigo®). Astellas Pharma Europe LTD provides enzalutamide (Xtandi™).

European Organisation for Research and Treatment of Cancer

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.